LITTLE KNOWN FACTS ABOUT PROTEINASE K INHIBITOR.

The lack of ER, HER2, and PR expression in triple destructive breast tumors offers a significant challenge in creating specific therapies (Katz and Alsharedi 2017). To address this, numerous reports have appeared into precise procedures which can be specific in TNBC and not using a wider systemic influence (Katz and Alsharedi 2017). Gene expression